Retinal Vascular Occlusion – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Retinal Vascular Occlusion – Drugs In Development, 2024 report and make more profitable business decisions.
Retinal vascular occlusion is a condition that affects the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. It occurs when a blood vessel is blocked by a clot or compressed by another vessel, preventing blood from reaching or leaving the retina. This can cause vision loss or blindness in the affected eye. There are two main types of retinal vascular occlusion: retinal artery occlusion and retinal vein occlusion. Both types can have serious complications, such as swelling, bleeding, or abnormal blood vessel growth in the eye. Retinal vascular occlusion is more common in middle-aged and older people, and in people with risk factors such as atherosclerosis, high blood pressure, diabetes, or blood clotting disorders. The diagnosis is based on a comprehensive eye exam and tests such as a fundus photography, fluorescein angiography, or optical coherence tomography. The treatment depends on the type and severity of the occlusion, and may include medication injections, laser therapy, or surgery. The goal of treatment is to prevent or reduce vision loss and complications.
The Retinal Vascular Occlusion drugs in development market research report provide comprehensive information on the therapeutics under development for Retinal Vascular Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vascular Occlusion and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Retinal Vascular Occlusion | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 38 molecules, with 38 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Retinal Vascular Occlusion therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Retinal Vascular Occlusion pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Retinal Vascular Occlusion treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAffaMed Therapeutics US Inc
Allgenesis Biotherapeutics Inc
ANBITION Srl
Annexin Pharmaceuticals AB
AsclepiX Therapeutics Inc
AskGene Pharma Inc
Avirmax Inc
Calpain Therapeutics Pty Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chugai Pharmaceutical Co Ltd
Drive Therapeutics LLC
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Glaukos Corp
Huabo Biopharm (Shanghai) Co Ltd
KALA BIO Inc
Luye Pharma Group Ltd
Novartis AG
Novelty Nobility Inc
Ocular Therapeutix Inc
Oculis Holding AG
Outlook Therapeutics Inc
Oxular Ltd
Perfuse Therapeutics Inc
RevOpsis Therapeutics Corp
Ripple therapeutics Corp
Senju Pharmaceutical Co Ltd
SIFI SpA
Thea Open Innovation SASU
Theratocular Biotek Co Ltd
Uni-Bio Science Group Ltd
Valitor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Retinal Vascular Occlusion reports